Pharm-Olam is now Allucent. Learn More
When you choose a team with the right kind of clinical trial oncology experience, you set your study up for success. For more than 20 years, we have specialized in oncology clinical trials supporting global clinical research across a wide variety of indications including:
Accelerating early phase research is critical to sponsors and patients. With over 50% of PM’s and over 60% of CRA’s at Pharm-Olam experienced in early phase oncology trials including complex adaptive designs and FIH trials, and with a specialization in early phase hematology-oncology research, including leukemia, lymphoma, and myeloma, we are ideally positioned to expedite your next Phase I-II trial.
Our oncology CRO team has invested in advantageous site and vendor relationships with process optimizations and checkpointed cohort management techniques to expedite your early-phase study.
At Pharm-Olam, we maintain therapeutically-aligned staff with deep expertise in Oncology. From solid tumor to liquid tumor, our oncology CRO staff have the expertise you need to go the distance.
Staff with Oncology study expertise.
Pharm-Olam has championed small pharma and biotech companies since the earliest developments in the field. Over 85% of our experience is with small and emerging pharma and biotech. We continue those efforts today. With Pharm-Olam, you will find an agile Clinical Research Organization (CRO) focused on finding trial-specific solutions to accelerate your study execution. We go the distance – helping you create a healthier world.
Our Hematology experience includes liquid tumor expertise as well as numerous non-cancerous hematology diseases. From rare hematology disorders to common diseases, we have gone the distance for our patients and are ready to support your hematology drug development.
It’s important to choose a team that has the right kind of therapeutic experience for your clinical trial. Our teams have executed studies for hematology treatments across a wide variety of indications.
Pharm-Olam was hired by a sponsor to run a PD-1 Inhibitor Phase I oncology study in solid tumor patients. The study moved swiftly and we completed enrollment 78 days early.
Pharm-Olam was hired by a sponsor to run a PD-1 Inhibitor Phase I oncology study in solid tumor patients. The study moved swiftly and we completed enrollment 78 days early.
Cohort management is part of conducting dose-escalation studies. This article outlines the methods our teams utilize in early-phase oncology research.
Read More
As an oncology-focused CRO with 20+ years of experience in managing oncology and hematology trials, Pharm-Olam combines an understanding of clinical trial complexities with proven strategies to ensure study goals are met in a timely and efficient manner. Download the fact sheet to learn more about our oncology capabilities.
Download
A Pharm-Olam overview of a Phase II/III study for the treatment of Recurrent Glioblastoma / Anaplastic Astrocytoma.
Learn More
